In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.

UB, Hagemann; K, Wickstroem; E, Wang; AO, Shea; K, Sponheim; J, Karlsson; RM, Bjerke; OB, Ryan; AS, Cuthbertson

doi:10.1158/1535-7163.mct-16-0251

Public

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.

Shared by NobleBlocks on Aug 17, 2016 • 12:00 AM UTC

Authors:

Hagemann UB

Wickstroem K

Wang E

Abstract

The clinical efficacy of the first approved alpha pharmaceutical, Xofigo (radium-223 dichloride, 223RaCl2), has stimulated significant interest in the development of new alpha-particle emitting drugs in oncology. Unlike radium-223 (223Ra), the parent radionuclide thorium-227 (227Th) is able to form ...

Discussions